These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 26429872)

  • 1. Application of functional vincristine plus dasatinib liposomes to deletion of vasculogenic mimicry channels in triple-negative breast cancer.
    Zeng F; Ju RJ; Liu L; Xie HJ; Mu LM; Zhao Y; Yan Y; Hu YJ; Wu JS; Lu WL
    Oncotarget; 2015 Nov; 6(34):36625-42. PubMed ID: 26429872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liposomes, modified with PTD(HIV-1) peptide, containing epirubicin and celecoxib, to target vasculogenic mimicry channels in invasive breast cancer.
    Ju RJ; Li XT; Shi JF; Li XY; Sun MG; Zeng F; Zhou J; Liu L; Zhang CX; Zhao WY; Lu WL
    Biomaterials; 2014 Aug; 35(26):7610-21. PubMed ID: 24912818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-angiogenic treatment promotes triple-negative breast cancer invasion via vasculogenic mimicry.
    Sun H; Zhang D; Yao Z; Lin X; Liu J; Gu Q; Dong X; Liu F; Wang Y; Yao N; Cheng S; Li L; Sun S
    Cancer Biol Ther; 2017 Apr; 18(4):205-213. PubMed ID: 28278077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy in Treating Lung Metastasis of Invasive Breast Cancer with Functional Vincristine Plus Dasatinib Liposomes.
    Zeng F; Ju RJ; Liu L; Xie HJ; Mu LM; Lu WL
    Pharmacology; 2018; 101(1-2):43-53. PubMed ID: 28988243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Destruction of vasculogenic mimicry channels by targeting epirubicin plus celecoxib liposomes in treatment of brain glioma.
    Ju RJ; Zeng F; Liu L; Mu LM; Xie HJ; Zhao Y; Yan Y; Wu JS; Hu YJ; Lu WL
    Int J Nanomedicine; 2016; 11():1131-46. PubMed ID: 27042063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting Epirubicin Plus Quinacrine Liposomes Modified with DSPE-PEG2000-C(RGDfK) Conjugate for Eliminating Invasive Breast Cancer.
    Sun MG; Shi JF; Li XY; Zhao Y; Ju RJ; Mu LM; Yan Y; Li XT; Zeng F; Lu WL
    J Biomed Nanotechnol; 2015 Aug; 11(8):1339-53. PubMed ID: 26295137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Combination of Targeted Sunitinib Liposomes and Targeted Vinorelbine Liposomes for Treating Invasive Breast Cancer.
    Shi JF; Sun MG; Li XY; Zhao Y; Ju RJ; Mu LM; Yan Y; Li XT; Zeng F; Lu WL
    J Biomed Nanotechnol; 2015 Sep; 11(9):1568-82. PubMed ID: 26485927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of Vasculogenic Mimicry and Angiogenesis by an Anti-EGFR IgG1-Human Endostatin-P125A Fusion Protein Reduces Triple Negative Breast Cancer Metastases.
    Shin SU; Cho HM; Das R; Gil-Henn H; Ramakrishnan S; Al Bayati A; Carroll SF; Zhang Y; Sankar AP; Elledge C; Pimentel A; Blonska M; Rosenblatt JD
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor efficacy of Lf modified daunorubicin plus honokiol liposomes in treatment of brain glioma.
    Liu S; Zhang SM; Ju RJ; Xiao Y; Wang X; Song XL; Gu LY; Cheng L; Li XT; Chen GR
    Eur J Pharm Sci; 2017 Aug; 106():185-197. PubMed ID: 28583810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Twist1 expression induced by sunitinib accelerates tumor cell vasculogenic mimicry by increasing the population of CD133+ cells in triple-negative breast cancer.
    Zhang D; Sun B; Zhao X; Ma Y; Ji R; Gu Q; Dong X; Li J; Liu F; Jia X; Leng X; Zhang C; Sun R; Chi J
    Mol Cancer; 2014 Sep; 13():207. PubMed ID: 25200065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanosized functional miRNA liposomes and application in the treatment of TNBC by silencing Slug gene.
    Yan Y; Li XQ; Duan JL; Bao CJ; Cui YN; Su ZB; Xu JR; Luo Q; Chen M; Xie Y; Lu WL
    Int J Nanomedicine; 2019; 14():3645-3667. PubMed ID: 31190817
    [No Abstract]   [Full Text] [Related]  

  • 12. Cetuximab PET delineated changes in cellular distribution of EGFR upon dasatinib treatment in triple negative breast cancer.
    McKnight BN; Kim S; Boerner JL; Viola NT
    Breast Cancer Res; 2020 Apr; 22(1):37. PubMed ID: 32295603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of WT1 isoforms in vasculogenic mimicry and metastatic potential of human triple negative breast cancer cells.
    Bissanum R; Lirdprapamongkol K; Svasti J; Navakanitworakul R; Kanokwiroon K
    Biochem Biophys Res Commun; 2017 Dec; 494(1-2):256-262. PubMed ID: 29024629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation.
    Andey T; Sudhakar G; Marepally S; Patel A; Banerjee R; Singh M
    Mol Pharm; 2015 Apr; 12(4):1105-20. PubMed ID: 25661724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer.
    Jang NY; Kim DH; Cho BJ; Choi EJ; Lee JS; Wu HG; Chie EK; Kim IA
    BMC Cancer; 2015 Mar; 15():89. PubMed ID: 25884663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multifunctional liposomes loaded with paclitaxel and artemether for treatment of invasive brain glioma.
    Li XY; Zhao Y; Sun MG; Shi JF; Ju RJ; Zhang CX; Li XT; Zhao WY; Mu LM; Zeng F; Lou JN; Lu WL
    Biomaterials; 2014 Jul; 35(21):5591-604. PubMed ID: 24726749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multi-targeting NGR-modified liposomes recognizing glioma tumor cells and vasculogenic mimicry for improving anti-glioma therapy.
    Huang D; Zhang S; Zhong T; Ren W; Yao X; Guo Y; Duan XC; Yin YF; Zhang SS; Zhang X
    Oncotarget; 2016 Jul; 7(28):43616-43628. PubMed ID: 27283987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyaluronic acid modified daunorubicin plus honokiol cationic liposomes for the treatment of breast cancer along with the elimination vasculogenic mimicry channels.
    Ju RJ; Cheng L; Qiu X; Liu S; Song XL; Peng XM; Wang T; Li CQ; Li XT
    J Drug Target; 2018 Nov; 26(9):793-805. PubMed ID: 29334266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Granzyme B-based cytolytic fusion protein targeting EpCAM specifically kills triple negative breast cancer cells in vitro and inhibits tumor growth in a subcutaneous mouse tumor model.
    Amoury M; Kolberg K; Pham AT; Hristodorov D; Mladenov R; Di Fiore S; Helfrich W; Kiessling F; Fischer R; Pardo A; Thepen T; Hussain AF; Nachreiner T; Barth S
    Cancer Lett; 2016 Mar; 372(2):201-9. PubMed ID: 26806809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aptamer-mediated impairment of EGFR-integrin αvβ3 complex inhibits vasculogenic mimicry and growth of triple-negative breast cancers.
    Camorani S; Crescenzi E; Gramanzini M; Fedele M; Zannetti A; Cerchia L
    Sci Rep; 2017 Apr; 7():46659. PubMed ID: 28425453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.